Version 1
: Received: 17 June 2024 / Approved: 17 June 2024 / Online: 18 June 2024 (03:13:33 CEST)
How to cite:
Kikwango, E. M.; Akilimali, P. Z.; Tran, N. T. T.; Mbala, P. K.; Ahuka, S. M.; Muyembe, J. J. T. Impact of Most Promising Ebola Therapies on Survival: A Secondary Analysis during the Tenth Outbreak in the Democratic Republic of Congo. Preprints2024, 2024061154. https://doi.org/10.20944/preprints202406.1154.v1
Kikwango, E. M.; Akilimali, P. Z.; Tran, N. T. T.; Mbala, P. K.; Ahuka, S. M.; Muyembe, J. J. T. Impact of Most Promising Ebola Therapies on Survival: A Secondary Analysis during the Tenth Outbreak in the Democratic Republic of Congo. Preprints 2024, 2024061154. https://doi.org/10.20944/preprints202406.1154.v1
Kikwango, E. M.; Akilimali, P. Z.; Tran, N. T. T.; Mbala, P. K.; Ahuka, S. M.; Muyembe, J. J. T. Impact of Most Promising Ebola Therapies on Survival: A Secondary Analysis during the Tenth Outbreak in the Democratic Republic of Congo. Preprints2024, 2024061154. https://doi.org/10.20944/preprints202406.1154.v1
APA Style
Kikwango, E. M., Akilimali, P. Z., Tran, N. T. T., Mbala, P. K., Ahuka, S. M., & Muyembe, J. J. T. (2024). Impact of Most Promising Ebola Therapies on Survival: A Secondary Analysis during the Tenth Outbreak in the Democratic Republic of Congo. Preprints. https://doi.org/10.20944/preprints202406.1154.v1
Chicago/Turabian Style
Kikwango, E. M., Steve M Ahuka and Jean Jacque T Muyembe. 2024 "Impact of Most Promising Ebola Therapies on Survival: A Secondary Analysis during the Tenth Outbreak in the Democratic Republic of Congo" Preprints. https://doi.org/10.20944/preprints202406.1154.v1
Abstract
Abstract:
Background: MAb114, REGN-EB3, Remdesivir, and ZMapp, which are monoclonal antibody-based treatments, have been compared and shown to be promising therapies against the Ebola Virus Disease (EVD). There has been no comparison between these med-ications and standard treatment (without antiviral). Our study aimed to examine the con-tribution of each regimen compared to standard treatment on the survival of EVD patients and assess whether this association was modified by EVD vaccination (rVSV-ZEBOV Ebola vaccine) status.
Methodology: We performed a secondary analysis of data obtained from four EVD treatment centers located in Katwa, Mangina, Butembo, and Beni in the North Kivu region. The main outcome measure was mortality within a 28-day period. A Cox model was used to identify predictors of survival in hospitalized EVD patients.
Results: Vaccinated EVD patients were 1.7 times less likely to die compared to unvac-cinated patients (3.70 days vs. 5.00 days; p=0.0002). Delaying care and treatment at EVD treatment centres increased mortality risk by 5% for each day following symptom onset. Compared to the standard treatment group, adjusted mortality rates were significantly re-duced in the groups receiving MAb114 (0.29, p
Public Health and Healthcare, Public Health and Health Services
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
